Article
Rates of ERBB2 Alterations across Melanoma Subtypes and a Complete Response to Trastuzumab Emtansine in an ERBB2-Amplified Acral Melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Dec 2018
Gottesdiener Lee S, O'Connor Shannon, Busam Klaus J, Won Helen, Solit David B, Hyman David M, Shoushtari Alexander N
Abstract excerpt
PURPOSE: Patients with BRAF V600 wild-type melanoma whose tumors progress on checkpoint inhibition currently have limited therapeutic options, and additional rational treatment targets are needed. ERBB2 alterations may be amenable to targeted inhibition, but the rate of ERBB2 alterations across melanoma subtypes is not well described. PATIENTS AND METHODS: All patients with nonuveal melanoma (cutaneous, acral,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.